Dehydroepiandrosterone (DHEA) is the latest example of a product, once available only as a dietary supplement, becoming a mainstream drug. The U.S. Food and Drug Administration (FDA) has just approved a new DHEA product called Intrarosa (prasterone) for treating moderate-to-severe dyspareunia, in postmenopausal women.
The drug, a once-daily vaginal insert, was evaluated in two 12-week clinical trials including 406 healthy postmenopausal women. When compared to placebo, Intrarosa was shown to reduce pain during sexual intercourse. This is the first product containing DHEA to be FDA approved.
The information in this brief report is intended for informational purposes only, and is meant to help users better understand health concerns. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions. Copyright © 2024 NatMed. Commercial distribution or reproduction prohibited. NatMed is the leading provider of high-quality, evidence-based, clinically-relevant information on natural medicine, dietary supplements, herbs, vitamins, minerals, functional foods, diets, complementary practices, CAM modalities, exercises and medical conditions. Monograph sections include interactions with herbs, drugs, foods and labs, contraindications, depletions, dosing, toxicology, adverse effects, pregnancy and lactation data, synonyms, safety and effectiveness.
